Biotech firms prioritize change of control in merger talks

06/3/2009 | Reuters

Many merger negotiations in the biotech industry have stumbled over the issue of control, analysts said. Change of control intensified the proxy fight involving Amylin Pharmaceuticals' shareholders, and it also resulted in an arbitration battle between Johnson & Johnson and Schering-Plough after the latter agreed to merge with Merck & Co.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID